Generic Name: budesonide
Brand Name: Jorveza
Manufacturer: AVIR Pharma Inc
Therapeutic Area: Maintenance of Eosinophilic esophagitis in adults
Indications: Indicated for the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).
Manufacturer Requested Reimbursement Criteria1: For the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE), as per Health Canada indication.
Submission Type: Initial
NOC Status at Filing: Pre NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient/clinician input open | October 07, 2020 |
| Call for patient/clinician input closed | November 26, 2020 |
| Clarification: - Patient input submission received from the EOS Network (formerly FABED ), Food Allergy Canada and the Gastrointestinal Society | |
| Submission received | November 05, 2020 |
| Submission accepted | November 19, 2020 |
| Review initiated | November 20, 2020 |
| Draft CADTH review report(s) provided to sponsor for comment | February 18, 2021 |
| Deadline for sponsors comments | March 01, 2021 |
| CADTH responses on draft review report(s) provided to sponsor | April 09, 2021 |
| Expert committee meeting (initial) | April 21, 2021 |
| Draft recommendation issued to sponsor | May 03, 2021 To May 05, 2021 |